论文部分内容阅读
为了解肺表面活性物质在预防和治疗早产儿呼吸窘迫综合征方面的作用,我们对115例孕期为26周～30周的早产儿进行了对比研究。结果提示:应用肺表面活性物质后,治疗组肺功能较对照组明显改善;无支气管肺发育不全早产儿生存率明显增高;呼吸机应用时间及总住院时间明显缩短。但对总生存率及并发症无明显影响。
To understand the role of pulmonary surfactant in the prevention and treatment of respiratory distress syndrome in preterm infants, we compared 115 preterm infants between the ages of 26 weeks and 30 weeks of pregnancy. The results suggest that the lung function of the treatment group was significantly improved compared with the control group after application of pulmonary surfactant. The survival rate of premature infants without bronchopulmonary dysplasia was significantly increased, and the ventilator application time and total hospitalization time were significantly shortened. But no significant effect on the overall survival rate and complications.